Company / Capital Expenditures
Gain Therapeutics, Inc. Capital Expenditures History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$15.4K
FY2024
5-year range
$15.4K / $119.0K
FY2021-FY2024
Trend
-87.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $94,212 to $15,358 over the past 2 years.
Based on SEC 10-K filings.
$15,358 in FY2024 with a 3-year CAGR of -9.7%.
Declined from $94,212 to $15,358 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -9.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -9.7%, indicating a declining trend.
- In FY2024, capital expenditures decreased 87.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $15.4K | -87.1% |
| FY2023 | $119.0K | +26.3% |
| FY2022 | $94.2K | +352.4% |
| FY2021 | $20.8K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026